Just last week Bristol-Myers Squibb updated the investment community on its pipeline and business strategy.
The company will soon seek regulatory approval for ipilimumab, a novel immunotherapy, in patients previously treated for melanoma. BMS will also try to gain approval in 2010 for its chronic myelogenous leukemia (CML) drug Sprycel® as a first-line treatment for CML patients.
Brivanib, necitumumab and XL-184 are other experimental cancer agents that BMS has in late-stage development. Take a look at the company's comprehensive oncology pipeline here.
Recent Oncology Pipeline News
Transgene Sells Option on Cancer Vaccine to Novartis
(Bloomberg) Mar 10, 2010 - Transgene SA, the French biotechnology company backed by the billionaire Merieux family, sold Novartis AG an option on rights to the experimental TG4010 cancer vaccine in a deal that may fetch as much as $960 million.
read article »
Abbott Enhances Pharmaceutical Pipeline With Acquisition of Facet Biotech
(Yahoo! Finance) Mar 9, 2010 - Provides promising biologic intended to treat multiple sclerosis and compounds that complement Abbott's existing diverse oncology program.
read article »
Read ALL News »
Clinical Trial Resource Window
The FDA just granted priority review to Novartis's Tasigna® as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. If approved later this year, Tasigna will be the first treatment in this indication since the standard of care Gleevec.
Data from the ENESTnd Phase 3 clinical trial showed Tasigna's superior efficacy in the first head-to-head comparison against Gleevec in newly diagnosed Ph+ CML patients.
Phase 2 and 3 studies of other "orphan' leukemias like Ph+ CML are ongoing. Read up on "Selected Trials in Adult Leukemia" from Clinical Lymphoma, Myeloma & Leukemia's February 2010 issue, to see what we're talking about. We'd like to acknowledge Clinical Trials List Editor, Jorge E. Cortés, for providing the content.
Stay ahead of market moving oncology events and peer into the future of the oncology industry with the new OBR Radar.